Duloxetine in the treatment of major depressive disorder

David J Goldstein, David J Goldstein

Abstract

Since depression impacts all body systems, antidepressant treatments should relieve both the emotional and physical symptoms of depression. Duloxetine demonstrated antidepressant efficacy at a dose of 60 mg qd in two placebo-controlled, randomized, double-blind studies and significantly improved remission rates compared with placebo. Duloxetine-treated patients had significant reduction in severity of the symptoms of depression as assessed by the HAM-D(17), anxious symptoms as measured by the HAM-A and quality of life measures compared to placebo. Duloxetine also improved somatic symptoms, particularly painful symptoms which may have contributed to significantly improved remission rates compared to placebo. Approximately 10% of the 1139 patients with major depressive disorder in placebo-controlled trials discontinued treatment due to an adverse event, compared to 4% of the 777 patients receiving placebo. In addition to nausea (1.4% incidence), which was the most common reason for discontinuation, dizziness, somnolence, and fatigue were the most common AEs reported as reasons for discontinuation and all were considered drug-related. Duloxetine treatment lacks effects on ECG, increases heart rate, and has little effect on blood pressure or weight.

Keywords: SNRI; antidepressant; depression; duloxetine; pain; quality of life.

References

    1. [APA] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric Association; 1994.
    1. [APA] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, Text Revision. Washington DC: American Psychiatric Association; 2000.
    1. AnonymousMedical Economics Staff2006Cymbalta® Physicians Desk Reference 60th edMontvale, NJ: Thomson Healthcare/Medical Economics Co; 1729–35.
    1. Arnold L, Lu Y, Detke M, et al. A double-blind multicentral trial comparing duloxetine with placebo in the treatment of patients with fibromyalgia with and without major depressive disorder. Arthritis Rheum. 2004;50:2974–84.
    1. Arnold LM, Rosen A, Yili Lu Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5–15.
    1. Bailey RK, Mallinckrodt CH, Wohlreich MM, et al. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy. J Nat Med Assoc. 2006;98:437–47.
    1. Ballenger JC. Clinical evaluation of venlafaxine. J Clin Psychopharmacol. 1996;16(Suppl 2):29S–35S.
    1. Belsher G, Costello CG. Relapse after recovery from unipolar depression: a critical review. Psychol Bull. 1988;104:84–96.
    1. Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry. 1995;56:229–37.
    1. Berk M, du Plessis AD, Birkett M, et al. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group. Int Clin Psychopharmacol. 1997;12:137–40.
    1. Bosc M. Assessment of social functioning in depression. Compr Psychiatry. 2000;41:63–9.
    1. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res. 2005;39:43–53.
    1. Bymaster FP, Lee TC, Knadler MP, et al. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des. 2005;11:1475–93.
    1. Casacalenda N, Perry JC, Looper K. Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions. Am J Psychiatry. 2002;159:1354–60.
    1. Cohen LJ, Harris PA, Ticknor CB. Depression: new perspectives, understanding, and treatments. J Manag Care Pharm. 2004;10(Suppl):S1–25.
    1. Corey-Lisle PK, Nash R, Stang PE, et al. Response, partial response, and non-response in primary care treatment of depression. Arch Int Med. 2004;164:1197–204.
    1. Croft H, Settle E, Jr, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther. 1999;21:643–58.
    1. Cronkite R. Life circumstances and personal resources as predictors of the ten-year course of depression. Am J Community Psychol. 1998;26:255–80.
    1. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl) 1986;90:131–8.
    1. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord. 1990;18:289–99.
    1. Delgado PL, Brannan SK, Mallinckrodt CH, et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry. 2005;66:686–92.
    1. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002a;63:308–315.
    1. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002b;36:383–90.
    1. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004;14:457–70.
    1. Dunbar GC, Claghorn JL, Kiev A, et al. A comparison of paroxetine and placebo in depressed outpatients. Acta Psychiatr Scand. 1993;87:302–5.
    1. Dunner DL, D’Souza DN, Kajdasz DK, et al. Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression. J Affect Disord. 2005;87:115–9.
    1. Dunner DL, Goldstein DJ, Mallinckrodt C, et al. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety. 2003;18:53–61.
    1. Eli Lilly and Co. Data on File: AMCP Formatted Formulary Submission Document For Cymbalta® duloxetine HCl Delayed-release Capsules. Eli Lilly and Co, Inc, ; Indianapolis IN, USA: 2004. September 30. 2004.
    1. Ellingrod VL, Perry PJ. Nefazodone: a new antidepressant. Am J Health Syst Pharm. 1995;52:2799–812.
    1. Fava M, Mallinckrodt CH, Detke MJ, et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatr. 2004;65:521–30.
    1. Feighner JP, Overo K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry. 1999;60:824–30.
    1. Gaster B, Holroyd J. St. John’s wort for depression: a systematic review. Arch Intern Med. 2000;160:152–6.
    1. Gerber PD, Barrett JE, Barrett JA, et al. The relationship of presenting physical complaints to depressive symptoms in primary care patients. J Gen Int Med. 1992;7:170–3.
    1. Gorman JM. Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60(Suppl 17):9–13.
    1. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109–18.
    1. Goldstein DJ, Lu Y, Detke MJ, et al. Effects of duloxetine on painful physical symptoms associated with depression. Psychosom. 2004a;45:17–28.
    1. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004b;24:389–399.
    1. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry. 2002;63:225–231.
    1. Goldstein DJ, Potter WZ. Biological Theories of Depression and Implications for Current and New Treatments. In: Ciraulo DA, Shader RI, editors. Pharmacotherapy of Depression. Totowa, NJ: Humana Press; 2004. pp. 1–32.
    1. Goldstein M, Gorman JM, Marek RG, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277:333–340. 38.
    1. Greco T, Eckert G, Kroenke K. The outcome of physical symptoms with treatment of depression. J Gen Intern Med. 2004;19:813–8.
    1. Greist J, McNamara RK, Mallinckrodt CH, et al. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 2004
    1. Gureje O, Simon GE, Ustun TB, et al. Somatization in cross-cultural perspective: a World Health Organization study in primary care. Am J Psychiatry. 1997;154:989–95.
    1. Gureje O, Von Korff M, Simon GE, et al. Persistent pain and well-being: a World Health Organization Study in Primary Care. JAMA. 1998;280:147–51.
    1. Hays RD, Wells KB, Sherbourne CD, et al. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry. 1995;52:11–9.
    1. Herrman H, Patrick DL, Diehr P, et al. Longitudinal investigation of depression outcomes in primary care in six countries: the LIDO study. Functional status, health service use and treatment of people with depressive symptoms. Psychol Med. 2002;32:889–902.
    1. Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277:333–40.
    1. Holliday SM, Plosker GL. Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy. Drugs Aging. 1993;3:278–99.
    1. Jackson JL, Houston JS, Hanling SR, et al. Clinical predictors of mental disorders among medical outpatients. Arch Int Med. 2001;161:875–9.
    1. Johnson JA, Coons SJ, Ergo A, et al. Valuation of EuroQOL EQ-5D health states in an adult US sample. Pharmacoeconomics. 1998;13:421–33.
    1. Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA. 2003;289:3152–60.
    1. Keller MB, Lavori PW, Rice J, et al. The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: a prospective follow-up. Am J Psychiatry. 1986;143:24–28.
    1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication NCS-R. JAMA. 2003;289:3095–105.
    1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prel-valence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19.
    1. Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry. 1996;(Suppl 30):17–30.
    1. Kessler RC, Zhao S, Blazer DG, et al. Prevalence, correlates and course of minor depression and major depression in the national Comorbidity survey. J Affect Disord. 1997;45:19–30.
    1. Klerman G, Weissman M. The course, morbidity, and costs of depression. Arch Gen Psychiatry. 1992;49:831–4.
    1. Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE. Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials. J Clin Psychiatry. 2006;67:761–70.
    1. Kroenke K, Price RK. Symptoms in the community: prevalence, classification, and psychiatric comorbidity. Arch Intern Med. 1993;153:2474–80.
    1. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;286:2947–55.
    1. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1992;49:769–73.
    1. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Disp. 2003;31:1142–50.
    1. Mallinckrodt CH, Raskin J, Wohlreich MM, et al. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. BMC Psychiatry. 2004;4:26.
    1. Mallinckrodt CH, Watkin JG, Liu C, et al. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features. BMC Psychiatry. 2005;5:1.
    1. Mason J, Freemantle N, Eccles M. Fatal toxicity associated with antidepressant use in primary care. Br J Gen Pract. 2000;50:366–70.
    1. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale ASEX): reliability and validity. J Sex Marital Ther. 2000;26:25–40.
    1. McKenna SP, Hunt SM. A new measure of quality of life in depression: testing reliability and construct validity of the QLDS. Health Policy. 1992;22:321–30.
    1. Mulrow CD, Williams JW, Jr, Chiquette E, et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med. 2000;108:54–64.
    1. Nelson JC. Synergistic effects of 5-HT and NE. Depress Anxiety. 1998;7(Suppl 1):5–6.
    1. Nelson JC, Mazure CM, Bowers MB, Jr, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48:303–7.
    1. Nelson JC, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine for the treatment of major depressive disorder in older patients. Am J Geriatr Psychiatry. 2005;13:227–35.
    1. Patris M, Bouchard JM, Bougerol T, et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol. 1996;11:129–36.
    1. Penninx BW, Rejeski WJ, Pandya J, et al. Exercise and depressive symptoms: a comparison of aerobic and resistance exercise effects on emotional and physical function in older persons with high and low depressive symptomatology. J Gerontol B Psychol Sci Soc Sci. 2002;57:124–32.
    1. Perahia DG, Gilaberte I, Wang F, et al. Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry. 2006;188:346–53.
    1. Perahia DG, Kajdasz DK, Walker DJ, et al. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder. Int J Clin Pract. 2006;60:613–20.
    1. Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl. 2000;403:17–25.
    1. Posse M, Hallstrom T. Depressive disorders among somatizing patients in primary health care. Acta Psychiatr Scand. 1998;98:187–92.
    1. Raskin J, Goldstein DJ, Mallinckrodt CH, et al. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatr. 2003;64:1237–44.
    1. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346–56.
    1. Revicki DA, Simon GE, Chan K. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. J Fam Pract. 1998;47:446–52.
    1. Schulberg HC, Katon WJ, Simon GE, et al. Best clinical practice: guidelines for managing major depression in primary medical care. J Clin Psychiatry. 1999;60(Suppl 7):19–26.
    1. Sechter D, Troy S, Paternetti S, et al. A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. Eur Psychiatry. 1999;14:41–8.
    1. Sheehan D, Harnett-Sheehan K, Raj B. The measurement of disability. Int Clin Psychopharmacol. 1996;13:89–95.
    1. Simon GE, Von Korff M. Somatization and psychiatric disorder in the NIMH Epidemiologic Catchment Area study. Am J Psychiatry. 1991;148:1494–500.
    1. Simon GE, Von Korff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med. 1999;341:1329–35.
    1. Simon GE, Chisholm D, Treglia M, et al. Course of depression, health services costs, and work productivity in an international primary care study. Gen Hosp Psychiatry. 2002;24:328–35.
    1. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharm Ther. 2003;73:170–7.
    1. Skinner MH, Kuan HY, Skerjanec A, et al. Effect of age on the pharmacokinetics of duloxetine in women. Br J Clin Pharm. 2004;57:54–61.
    1. Stahl SM. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry. 2000;48:894–901.
    1. Suri A, Reddy S, Gonzales C, et al. Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. Int J Clin Pharm Ther. 2005;43:78–84.
    1. Sutor B, Rummans TA, Jowsey SG, et al. Major depression in medically ill patients. Mayo Clin Proc. 1998;73:329–37.
    1. Swindle RW, Cronkite RC, Moos RH. Risk factors for sustained nonremission of depressive symptoms: A four-year follow-up. J Nerv Ment Dis. 1998;186:462–9.
    1. Thase ME. Studying new antidepressants: if there were a light at the end of the tunnel, could we see it? J Clin Psychiatry. 2002;63(Suppl 2):24–8.
    1. Thase ME, Tran PV, Wiltse C, et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol. 2005;25:132–40.
    1. Tran PV, Bymaster FP, McNamara RK, et al. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol. 2003;23:78–86.
    1. Von Korff M, Simon G. The relationship between pain and depression. Br J Psychiatry Suppl. 1996;30:101–8.
    1. Ware JE, Snow KK, Kosinski M, et al. Comparison of methods for scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995;33(Suppl 4):AS264–79.
    1. Weiner RD, Coffey CE. Electroconvulsive therapy in the medical and neurological patient. In: Stoudemire A, Fogel BS, editors. Psychiatric Care of the Medical Patient. New York, NY: Oxford University Press; 1993.
    1. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989;262:914–9.
    1. Williams JW, Jr, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med. 2000;132:743–56.
    1. Wohlreich MM, Martinez JM, Mallinckrodt CH, et al. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol. 2005;25:552–60.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj